MedTrace Logo

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

NCT01530373 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-03-05

No results posted yet for this study

Summary

Hot flashes present a considerable problem for many breast cancer patients; these symptoms may be intensified by hormonal therapies, such as aromatase inhibitors or tamoxifen. This study examines the value of solifenacin (a muscarinic acetylcholine receptor antagonist) in reducing hot flashes, compared with clonidine (a medication often used for treating hot flashes).

Conditions

Interventions

DRUG

solifenacin

oral solifenacin 5.0 mg daily for 3 weeks

DRUG

Clonidine

oral clonidine 0.1 mg daily for 3 weeks

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Allen C Sherman, PhD · Universitiy of Arkansas for Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2027-07-31
Completion
2028-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01530373 on ClinicalTrials.gov